(Reuters) – Pfizer Inc and its partner BioNTech SE said on Tuesday that they had submitted an application to the U.S. health regulator for the emergency use authorization of their COVID-19 booster shot among children 5 to 11 years of age.
(Reporting by Amruta Khandekar; Editing by Sriraj Kalluvila)
